ALB and focal segmental glomerulosclerosis: Although to date there is no US Food and Drug Administration–approved pharmacological treatment for FSGS, reduction in proteinuria is widely regarded to be beneficial in management of patients with FSGS and is considered the primary goal of treatment to slow the progressive course of the disease.13 For patients with FSGS, nephrotic syndrome is defined as proteinuria >3.5 g/g plus serum albumin <30 g/L, while patients with a spot urine protein-to-creatinine ratio (UPCR) ≥3.5 g/g and no hypoalbuminemia have nephrotic-range proteinuria.4